MYBL2 and esophageal cancer: Previous studies have reported that B-Myb is overexpressed and associated with poor prognosis in a variety of cancers including breast cancer, non-small cell lung cancer, colorectal cancer, neuroblastoma, osteosarcoma, esophageal cancer, and multiple myeloma 4-11.